BS_N5DVEJXT
Supratentorial Ependymoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Supratentorial Ependymoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Supratentorial Ependymoma
- overall_survival_months
- 9.921156373193167
- age_years
- 0.63
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.453
- G2M_CHECKPOINT+0.449
- WNT_BETA_CATENIN_SIGNALING+0.409
- DNA_REPAIR+0.371
- NOTCH_SIGNALING+0.303
- MITOTIC_SPINDLE+0.178
- INTERFERON_ALPHA_RESPONSE+0.165
- MYC_TARGETS_V2+0.148
- MYC_TARGETS_V1+0.105
- SPERMATOGENESIS+0.086
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.429
- KRAS_SIGNALING_UP-0.420
- INFLAMMATORY_RESPONSE-0.415
- IL6_JAK_STAT3_SIGNALING-0.393
- PROTEIN_SECRETION-0.379
- COMPLEMENT-0.364
- TNFA_SIGNALING_VIA_NFKB-0.345
- IL2_STAT5_SIGNALING-0.294
- ANDROGEN_RESPONSE-0.279
- COAGULATION-0.254
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_N5DVEJXT | EPN | Supratentorial EPN | 0.928 |
| 2 | BS_5P1TN10Z | Embryonal tumors | — | 0.829 |
| 3 | BS_NB42PWZN | Supratentorial Ependymoma | — | 0.825 |
| 4 | BS_VAAHBH60 | Supratentorial Ependymoma | — | 0.824 |
| 5 | BS_1EN5V3XW | high-grade glioma | — | 0.820 |
| 6 | eb5ad680-6080-41fe-982e-e46f90c3849f | — | — | 0.815 |
| 7 | 19-007D5_Primary | — | — | 0.813 |
| 8 | TCGA-98-A53A-01A-11R-A262-07 | — | cohortSQ1 | 0.811 |
| 9 | BS_M0QYNVK8 | high-grade glioma | — | 0.809 |
| 10 | BS_K25F4J3V | ATRT | — | 0.806 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.453 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.449 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.409 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.371 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.303 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.178 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.165 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.148 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.105 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.086 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.077 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.039 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.019 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.018 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.014 | Idelalisib | — uncovered |